Mai Elzahry, Waleed Diab, Helmut Sinzinger
Background: Painful metastatic bone dissemination is a common complication of solid malignant tumors that can lead to severe morbidity. There are different treatment strategies currently available for pain relief. Among those, we obtained clinical experience with Sm-153 EDTMP.
Objective: It was to evaluate the overall therapeutic response in 110 patients who underwent a single dose of Sm-153 EDTMP therapy and report if there is a significant correlation of metastatic bone pain response with gender, pathology of primary cancer, patient’s age, extent of the metastatic bone dissemination.
Patients and methods: 110 cancer patients were included in this retrospective analysis, 63 (57.2%) males (age range; 52-89 years) and 47 (42.7%) females (age range: 35-84 y), their diagnosis were prostate and breast cancer, respectively. all patients performed conventional bone scintigraphy to prove the evidence of metastatic bone dissemination. Pain severity was assessed clinically and according to WHO Analgesia Scale.
Results: Out of 110 cancer patients received a therapeutic dose of 153 Sm- EDTMP for palliation of painful metastatic bone lesions, 93.6% (103/110) showed overall therapeutic response and 6.4% (7/110) showed no response at all. 61% (67/110) of patients were completely pain-free, 32.6% (36/110) were partially responded to therapy, that response shows insignificant relations with the patients gender, pathology of primary tumor, patients age as well as the extent of metastatic bone dissemination.
Conclusion: The results of this study showed that a single dose of Sm-153 EDTMP offers an effective treatment option in patients with painful metastatic bone disseminations irrespective to their gender, age, tumor pathology as well as to the bone lesions extent.
ఈ కథనాన్ని భాగస్వామ్యం చేయండి
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 